ERTS Wealth Advisors LLC trimmed its holdings in Amgen, Inc. (NASDAQ:AMGN) by 4.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,091 shares of the medical research company’s stock after selling 108 shares during the period. ERTS Wealth Advisors LLC’s holdings in Amgen were worth $385,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in AMGN. Carroll Financial Associates Inc. increased its holdings in shares of Amgen by 0.8% in the second quarter. Carroll Financial Associates Inc. now owns 7,436 shares of the medical research company’s stock worth $1,370,000 after purchasing an additional 58 shares during the last quarter. Lincoln Capital Corp increased its stake in Amgen by 0.3% during the second quarter. Lincoln Capital Corp now owns 21,483 shares of the medical research company’s stock worth $3,959,000 after acquiring an additional 58 shares during the last quarter. Slow Capital Inc. increased its stake in Amgen by 0.4% during the second quarter. Slow Capital Inc. now owns 13,799 shares of the medical research company’s stock worth $2,543,000 after acquiring an additional 58 shares during the last quarter. Nicholas Hoffman & Company LLC. increased its stake in Amgen by 5.0% during the second quarter. Nicholas Hoffman & Company LLC. now owns 1,207 shares of the medical research company’s stock worth $222,000 after acquiring an additional 58 shares during the last quarter. Finally, CWM LLC increased its stake in Amgen by 1.8% during the second quarter. CWM LLC now owns 3,271 shares of the medical research company’s stock worth $603,000 after acquiring an additional 59 shares during the last quarter. Institutional investors and hedge funds own 76.28% of the company’s stock.

Shares of AMGN traded up $1.83 during mid-day trading on Friday, reaching $195.83. 363,350 shares of the company’s stock traded hands, compared to its average volume of 2,890,083. The stock has a market cap of $118.06 billion, a P/E ratio of 13.60, a P/E/G ratio of 2.30 and a beta of 1.11. The stock’s 50-day moving average is $196.19 and its two-hundred day moving average is $185.15. Amgen, Inc. has a 12 month low of $166.30 and a 12 month high of $211.90. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, July 30th. The medical research company reported $3.97 EPS for the quarter, beating analysts’ consensus estimates of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a return on equity of 76.17% and a net margin of 33.78%. The company’s quarterly revenue was down 3.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.83 earnings per share. Research analysts predict that Amgen, Inc. will post 14.3 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 6th. Investors of record on Thursday, August 15th were issued a $1.45 dividend. The ex-dividend date of this dividend was Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.96%. Amgen’s payout ratio is 40.28%.

Several brokerages have weighed in on AMGN. Citigroup reissued a “buy” rating on shares of Amgen in a research note on Monday, August 12th. Wells Fargo & Co reissued a “market perform” rating and set a $220.00 price objective (up from $202.00) on shares of Amgen in a research note on Tuesday, August 27th. They noted that the move was a valuation call. BMO Capital Markets reissued a “buy” rating on shares of Amgen in a research note on Monday. Mizuho cut Amgen from a “buy” rating to a “neutral” rating and boosted their price objective for the stock from $208.00 to $212.00 in a research note on Monday, August 19th. They noted that the move was a valuation call. Finally, JPMorgan Chase & Co. set a $198.00 price objective on Amgen and gave the stock a “hold” rating in a research note on Friday, September 6th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company’s stock. Amgen presently has an average rating of “Hold” and an average price target of $217.33.

In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $187.58, for a total value of $375,160.00. Following the completion of the sale, the director now owns 16,336 shares in the company, valued at $3,064,306.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Cynthia M. Patton sold 13,426 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $208.07, for a total value of $2,793,547.82. Following the completion of the sale, the senior vice president now owns 32,648 shares of the company’s stock, valued at approximately $6,793,069.36. The disclosure for this sale can be found here. Insiders sold 17,851 shares of company stock valued at $3,659,900 in the last quarter. 0.25% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Further Reading: How accurate is the Rule of 72?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.